Nanoparticles encapsulating hepatitis B virus cytosine‐phosphate‐guanosine induce therapeutic immunity against HBV infection

Shujuan Lv, Jun Wang, Shuang Dou, Xianzhu Yang, Xiang Ni, Rui Sun, Zhigang Tian, Haiming Wei – 1 August 2013 – Infection with hepatitis B virus (HBV) is the most common cause of liver disease worldwide. However, because the current interferon (IFN)‐based treatments have toxic side effects and marginal efficacy, improved antivirals are essential.

Kinetic differences in the induction of interferon stimulated genes by interferon‐α and interleukin 28B are altered by infection with hepatitis C virus

Nikolaus Jilg, Wenyu Lin, Jian Hong, Esperance A. Schaefer, David Wolski, James Meixong, Kaku Goto, Cynthia Brisac, Pattranuch Chusri, Dahlene N. Fusco, Stephane Chevaliez, Jay Luther, Kattareeya Kumthip, Thomas J. Urban, Lee F. Peng, Georg M. Lauer, Raymond T. Chung – 1 August 2013 – Several genome‐wide association studies (GWAS) have identified a genetic polymorphism associated with the gene locus for interleukin 28B (IL28B), a type III interferon (IFN), as a major predictor of clinical outcome in hepatitis C.

Subscribe to